Annals of Surgical Oncology

, Volume 5, Issue 6, pp 473–482 | Cite as

Therapeutic node dissections in malignant melanoma

  • Constantine P. Karakousis
Surgical Oncology Forum


Background: Therapeutic lymphadenectomies involve the dissection and removal of clinically enlarged, histologically positive nodes at the regional nodal basin, in the absence of detectable distant disease.

Methods: The literature dealing with therapeutic lymphadenectomies in malignant melanoma was reviewed.

Results: The rate of wound complications varies with the particular nodal basin. The 5-year survival varies from 19% to 38%, with an average of 26%. Survival is affected primarily by the number of histologically positive nodes and extracapsular spread, and secondarily by the extent of disease at the various levels of the nodal basin, fixation of the nodes, and, probably, the preceding disease-free interval. Prognostic parameters of the primary lesion, e.g., thickness, ulceration, and location, also may have an effect on survival. The rate of local recurrence at the nodal basin after lymphadenectomy has varied from 0.8% to 52%. Adjuvant therapy with interferon alfa-2b has improved the 5-year disease-free survival from 26% to 37%.

Conclusions: Therapeutic node dissections in melanoma provide an appreciable 5-year survival rate, which is further augmented by adjuvant therapy. Many series report a significant rate of local recurrence at the nodal basin following therapeutic dissection. Complete lymphadenectomy reduces the rate of local failure with its attendant morbidity.

Key Words

Malignant melanoma therapeutic node dissection regional nodal recurrence nodal basin lymphadenectomy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs.N Engl J Med 1977;297:627–30.PubMedGoogle Scholar
  2. 2.
    Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma.Cancer 1978;41:948–56.PubMedGoogle Scholar
  3. 3.
    Balch CM, Soong S-J, Bartolucci AA, Urist MM, Karakousis CP, et al. Efficacy of an elective regional lymph node dissection of 1- to 4-mm thick melanomas for patients 60 years of age and younger.Ann Surg 1996;224:255–66.PubMedCrossRefGoogle Scholar
  4. 4.
    Morton DL, Wen D-R, Wong JH, et al. Technical details of intra-operative mapping for early stage melanoma.Arch Surg 1992;127:392–9.PubMedGoogle Scholar
  5. 5.
    Karakousis CP, Balch CM, Urist MM, Ross MI, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the multi-institutional randomized surgical trial.Ann Surg Oncol 1996;3:446–52.PubMedGoogle Scholar
  6. 6.
    Konstadoulakis M, Karakousis CP, Walsh D, Ricaniadis N. Survival of patients with stage IA malignant melanoma.Surg Oncol 1995;4:101–4.PubMedGoogle Scholar
  7. 7.
    Wong JH, Cagle LA, Morton DL. Surgical treatment of lymph nodes with metastatic melanoma from unknown primary site.Arch Surg 1987;122:1380–3.PubMedGoogle Scholar
  8. 8.
    Karakousis CP, Emrich LJ, Driscoll DL, Rao U. Survival after groin dissection for malignant melanoma.Surgery 1991;109:119–26.PubMedGoogle Scholar
  9. 9.
    Shaw JHF, Koea J. Morbidity of lymphadenectomy for melanoma.Surg Oncol Clin North Am 1992;1:195–203.Google Scholar
  10. 10.
    Kane M, McClay E, Bellet RE. Frequency of occult residual melanoma after excision of a clinically positive regional lymph node.Ann Surg 1987;205:88–9.PubMedGoogle Scholar
  11. 11.
    Karakousis CP, Rizos S, Driscoll DL. Residual nodal disease after excisional biopsy of a palpable, positive node in melanoma.Am J Surg 1994;168:69–70.PubMedCrossRefGoogle Scholar
  12. 12.
    Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma.Ann Surg Oncol 1997;4:252–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Buzaid AC, Tinoco L, Ross MI, Legha SS, Benjamin RS. Role of computed tomography in the staging of patients with loco-regional metastases of melanoma.J Clin Oncol 1995;13:2104–8.PubMedGoogle Scholar
  14. 14.
    Karakousis CP, Velez A, Driscoll DL, Takita H. Metastasectomy in malignant melanoma.Surgery 1994;115:295–302.PubMedGoogle Scholar
  15. 15.
    O'Brien CJ, Fisher SR. Neck dissection and parotidectomy. In: Balch CM, Houghton AN, Sober AJ, Soong S-j, eds.Cutaneous Melanoma. 3rd ed. St. Louis: Quality Medical Publishing, 1998:245–57.Google Scholar
  16. 16.
    O'Brien CJ, Peterson-Schaefer K, Ruark D, Coates AS, Menzie SJ, Harrison RI. Radical, modified and selective neck dissection for cutaneous malignant melanoma.Head Neck 1995;17:232–41.PubMedGoogle Scholar
  17. 17.
    Mansfield PF, Ames FC, Balch CM. Axillary lymph node dissection. In: Balch CM, Houghton AN, Sober AJ, Soong S-j, eds.Cutaneous Melanoma. 3rd ed. St. Louis: Quality Medical Publishing, 1998:259–68.Google Scholar
  18. 18.
    Balch CM. Axillary lymph node dissection: differences in goals and techniques when treating melanoma and breast cancer.Surgery 1990;108:118–9.PubMedGoogle Scholar
  19. 19.
    Coit DG. Extent of groin dissection for melanoma.Surg Oncol Clin North Am 1992;1:271–80.Google Scholar
  20. 20.
    Karakousis CP. The technique of popliteal lymph node dissection.Surg Gynecol Obstet 1980;151:420–3.PubMedGoogle Scholar
  21. 21.
    Coit DG, Peters M, Brennan MF. A prospective randomized trial of perioperative Cefazolin treatment in axillary and groin dissection.Arch Surg 1991;126:1366–72.PubMedGoogle Scholar
  22. 22.
    Urist MM, Maddox WA, Kennedy JE, Balch CM. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients.Cancer 1983;51:2152–6.PubMedGoogle Scholar
  23. 23.
    Stringer SP, Cassisi NJ. Radical and modified neck dissection. In: Bland K, Karakousis CP, Copeland E, eds.Atlas of Surgical Oncology. Philadelphia: WB Saunders, 1995;165–80.Google Scholar
  24. 24.
    Karakousis CP, Goumas W, Rao U, Driscoll DL. Axillary node dissection in malignant melanoma.Am J Surg 1991;162:202–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Karakousis CP, Hena MA, Emrich LJ, Driscoll DL. Axillary node dissection in malignant melanoma: Results and complications.Surg 1990;108:10–7.Google Scholar
  26. 26.
    Karakousis CP, Driscoll DL, Rose B, Walsh DL. Groin dissection in malignant melanoma.Ann Surg Oncol 1994;1:271–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Beitsch P, Balch C. Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node dissection.Am J Surg 1992;164:462–5.PubMedGoogle Scholar
  28. 28.
    Rapaport DP, Stadelman WK, Reintgen DS. Inguinal lymphadenectomy. In: Balch CM, Houghton AN, Sober AJ, Soong S-j, eds.Cutaneous Melanoma. 3rd ed. St. Louis: Quality Medical Publishing, 1998:269–80.Google Scholar
  29. 29.
    Stadelmann WK, Rapaport DP, Soong S-j, Reintgen DS, Buzaid AC, Balch CM. Prognostic clinical and pathologic features. In: Balch CM, Houghton AN, Sober AJ, Soong S-j, eds.Cutaneous Melanoma. 3rd ed. St. Louis: Quality Medical Publishing, 1998:11–35.Google Scholar
  30. 30.
    Tillman DM, Aitchison T, Watt DC, Mackie RM. Stage II melanoma in the West of Scotland, 1976–1985: prognostic factors for survival.Eur J Cancer 1991;27:870–6.PubMedGoogle Scholar
  31. 31.
    Buzaid AC, Ross MI, Soong S-j. Classification and staging. In: Balch CM, Houghton AN, Sober AJ, Soong S-j, eds.Cutaneous Melanoma. 3rd ed. St. Louis: Quality Medical Publishing, 1998:37–47.Google Scholar
  32. 32.
    Buzaid AC, Tinoco LA, Jendiroba D, et al. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma.J Clin Oncol 1995;13:2361–8.PubMedGoogle Scholar
  33. 33.
    Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic.Ann Surg 1991;214:491–9.PubMedGoogle Scholar
  34. 34.
    Bevilacqua RG, Coit DG, Rogatko A, Younes RN, Brennan MF. Axillary dissection in melanoma. Prognostic variables in node-positive patients.Ann Surg 1990;212:125–31.PubMedGoogle Scholar
  35. 35.
    Barth RJ Jr, Venzon DJ, Baker AR. The prognosis of melanoma patients with metastases to two or more lymph node areas.Ann Surg 1991;214:125–30.PubMedGoogle Scholar
  36. 36.
    Dale PS, Foshag LJ, Wanek LA, Morton DL. Metastasis of primary melanoma to two separate lymph node basins: prognostic significance.Ann Surg Oncol 1997;4:13–8.PubMedGoogle Scholar
  37. 37.
    O'Brien CJ, Peterson-Schaefer K, Stevens GN, et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma.Head Neck 1997;19:589–94.PubMedCrossRefGoogle Scholar
  38. 38.
    Coit DG. Prognostic factors in patients with melanoma metastatic to regional nodes.Surg Oncol Clin North Am 1992;1:281–95.Google Scholar
  39. 39.
    Warso MA, Das Gupta TK. Melanoma recurrence in a previously dissected nodal basin.Arch Surg 1994;129:252–5.PubMedGoogle Scholar
  40. 40.
    Kretschmer L, Lautenschlager C, Preusser KP, Fiedler H, Hetschkol. Axillary recurrence after lymph node excision in malignant melanoma.Langenbecks Arch fur Chirurgie 1993;378:4–11.Google Scholar
  41. 41.
    Kretschmer L, Lautenschlager C, Preusser KP, Ffiedler H. Inguinal recurrence after therapeutic lymphadenectomy in malignant melanoma.Langenbecks Arch fur Chirurgie 1993;378:211–6.Google Scholar
  42. 42.
    Byers RM. The role of modified neck dissection in the treatment of cutaneous melanoma of the head and neck.Arch Surg 1986;12:1338–41.Google Scholar
  43. 43.
    Monsour PD, Sause WT, Avent JM, Noyes RD. Local control following therapeutic nodal dissection for melanoma.J Surg Oncol 1993;54:18–22.PubMedGoogle Scholar
  44. 44.
    Karakousis CP, Driscoll DL. Positive deep nodes in the groin and survival in malignant melanoma.Am J Surg 1996;171:421–2.PubMedCrossRefGoogle Scholar
  45. 45.
    McCarthy JH, Haagensen CK-D, Herter FP. The role of groin dissection in the management of melanoma of the lower extremity.Ann Surg 1974;179:156–9.PubMedGoogle Scholar
  46. 46.
    Cohen MH, Schour L, Felix EL, et al. Staging laparotomy in the treatment of metastatic melanoma of the lower extremities.Ann Surg 1976;182:710–4.Google Scholar
  47. 47.
    Singletary SE, Schallenberger R, Guinee VF. Surgical management of groin nodal metastases from primary melanoma of the lower extremity.Surg Gynecol Obstet 1992;174:195–200.PubMedGoogle Scholar
  48. 48.
    Coit DG, Brennan MF. Extent of lymph node dissection in melanoma of the trunk or lower extremity.Arch Surg 1989;124:162–6.PubMedGoogle Scholar
  49. 49.
    Fortner JG, Booher RJ, Pack GT. Results of groin dissection for malignant melanoma in 220 patients.Surgery 1964;55:485–94.PubMedGoogle Scholar
  50. 50.
    Finck SJ, Giuliano AE, Mann D, Morton DL. Results of ilioinguinal dissection for stage II melanoma.Ann Surg 1982;196:180–6.PubMedGoogle Scholar
  51. 51.
    Jonk A, Kroon BB, Rumke P, van der Esch EP, Hart AA. Results of radical dissection of the groin in patients with stage II melanoma and histologically proved metastases of the iliac or obturator nodes, or both.Surg Gynecol Obstet 1988;167:28–32.PubMedGoogle Scholar
  52. 52.
    Kissin MW, Simpson DA, Easton D, White H, Westbury G. Prognostic factors related to survival and groin recurrence following therapeutic lymph node dissection for lower limb malignant melanoma.Br J Surg 1987;74:1023–6.PubMedGoogle Scholar
  53. 53.
    McNeer G, Das Gupta TK. Prognosis in malignant melanoma.Surgery 1964;56:512–8.Google Scholar
  54. 54.
    Cohen MH, Ketcham AS, Felix EL, et al. Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma.Ann Surg 1977;186:635–42.PubMedGoogle Scholar
  55. 55.
    Das Gupta TK. Results of treatment of 269 patients with primary cutaneous melanoma: a five-year prospective study.Ann Surg 1977;186:201–9.Google Scholar
  56. 56.
    Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma, III: prognostic factors in melanoma patients with lymph node metastases (stage II).Ann Surg 1981;193:377–88.PubMedGoogle Scholar
  57. 57.
    Callery C, Cochran AJ, Roe DJ, et al. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes.Ann Surg 1982;196:69–75.PubMedGoogle Scholar
  58. 58.
    Roses DF, Provet JA, Harris MN, Gumport SL, Dubin N. Prognosis of patients with pathologic stage II cutaneous malignant melanoma.Ann Surg 1985;201:103–7.PubMedGoogle Scholar
  59. 59.
    Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.J Clin Oncol 1996;14:7–17.PubMedGoogle Scholar
  60. 60.
    Burmeister BH, Smithers BM, Poulsen M, McLeod GR, Bryant G, Tripcong L, Thorpe C. Radiation therapy for nodal disease in malignant melanoma.World J Surg 1995;19:369–71.PubMedCrossRefGoogle Scholar
  61. 61.
    Strom EA, Ross MI. Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control.Ann Surg Oncol 1995;2:445–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Petrek JA, Blackwood MM. Axillary dissection: current practice and technique.Curr Probl Surg 1995;32:257–323.PubMedGoogle Scholar
  63. 63.
    Morton DL, Hoon DSB, Nizza JA, et al. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma.Ann N Y Acad Sci 1993;690:120–34.PubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 1998

Authors and Affiliations

  • Constantine P. Karakousis
    • 1
  1. 1.From the Department of SurgeryState University of New York at Buffalo, Millard Fillmore Health SystemBuffalo

Personalised recommendations